Sphingolipid production
By using an ester and hemolytic sphingolipid in the presence of a base, the high cost and product impurities of the hemolytic sphingolipid N-acylation method in the prior art are solved, and efficient and economical production of sphingolipids is achieved.
Patent Information
- Application Number
- CN202380023018.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-21
- Filing Date
- 2023-02-17
- Publication Date
- 2024-11-22
AI Technical Summary
Existing hemolytic sphingolipid N-acylation methods use expensive and toxic coupling reagents, or result in a mixture of N- and O-acylation products, requiring a lengthy and expensive purification process, making it difficult to efficiently produce sphingolipids.
Esters are used as acylating agents and react with hemolytic sphingolipid in an alcohol solvent in the presence of a base to achieve selective N-acylation of hemolytic sphingolipids and produce sphingolipids.
The efficient and economical N-acylation of hemolytic sphingolipids is achieved, the use of expensive and toxic agents is avoided, the purification process is simplified, and the production efficiency and product purity of sphingolipids are improved.
Smart Images

Figure BDA0005003900940000021 
Figure BDA0005003900940000031 
Figure BDA0005003900940000032
Abstract
Description
Technical Field
[0001] The present invention relates to a novel and efficient method for producing sphingolipids by N-acylation of lysosphingolipids (such as D-erythro-sphingosine or 6-hydroxy-D-erythro-sphingosine), their analogs or salts thereof. The method is based on the use of esters as acylating agents and is particularly suitable for the production of ceramides and glycosphingolipids. Background Art
[0002] Sphingolipids are an important class of polar lipids found primarily on the surface of eukaryotic cells. Sphingolipids are structurally characterized by a sphingoid base backbone and can be divided into different classes, such as ceramides and glycosphingolipids.
[0003] Ceramides are N-acylated sphingoid bases that lack an additional head group at the 1-position of the sphingoid base backbone, and wherein the N-acyl group of ceramide is typically derived from a fatty acid. Glycosphingolipids (GSLs) are glycoconjugates derived from ceramide, wherein the glycan moiety is linked to the 1-hydroxyl group of ceramide via a glycosidic bond.
[0004] Sphingolipids are involved in a variety of biological processes and play important structural and functional roles, such as cell-cell recognition, communication, and intercellular adhesion. In particular, GSLs (such as gangliosides) are found in the brain and play a role in neurological diseases, while ceramides are the main components of the stratum corneum lipid layer and play a major role in the water-retaining properties of the epidermis and the barrier function of the skin.
[0005] Therefore, sphingolipids have great potential as therapeutic agents, cosmetics and tools for studying important biological processes. However, they are not easily accessible for basic and clinical research. In fact, sphingolipids (such as ceramides and GSLs) are characterized by high structural complexity and their challenging preparation.
[0006] Sphingolipids such as ceramides and GSLs can be obtained by N-acylation of lysosphingolipids. Typically, lysosphingolipids are defined as sphingolipid breakdown products that lack an amide-linked fatty acid at the 2-position of the sphingoid base backbone. Thus, for each parent sphingolipid, there is a corresponding lysosphingolipid that has the same head group at the 1-position but lacks an amide-linked fatty acid at the 2-position (Hannun et al., Science 1989, 243, 500-507).
[0007] N-acylation of lysosphingolipids can be performed chemically or enzymatically.
[0008] Current chemical N-acylation methods are typically based on the use of amide bond coupling reagents such as N-hydroxysuccinimide (NHS), 1,3-dicyclohexylcarbodiimide (DCC), or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (Skolova et al., Biochim Biophys Acta Biomembr. 2017, 1859, 824-834, WO 0172701 A1) or sulfonyl chloride (US 5631356 A). Alternatively, esters of acids have been used for N-acylation of phytosphingosine and dihydrosphingosine (WO 2013038985A1, WO 2013094108 A1, EP0856510 A1, EP 0835864 A2, Drug.Del.Sci.Tech. 2014, 24, 689-693, Org.Process Res.Dev. 2019, 23, 452-461).
[0009] Current chemical methods for N-acylation of lysosphingolipids have several disadvantages, including the use of expensive and / or toxic coupling reagents that require the use of anhydrous solvents and / or the performance of the reactions in the exclusion of air.
[0010] Current enzymatic methods are based on the use of lipases (WO 1994026919 A1, US2011077302 A1); however, these lipases are typically not specific for the amino groups of lysosphingolipids but may also act on the hydroxyl groups, leading to the formation of a mixture of N- and O-acylated products and thus requiring lengthy and expensive purification of the target compound. Summary of the Invention
[0011] In a first aspect, the present invention relates to a method for producing a sphingolipid having formula (1):
[0012]
[0013] in
[0014] W is H or a glycosyl moiety,
[0015] R 1 is H, aryl or C 1-50 Hydrocarbyl, preferably C 1-15 Hydrocarbyl, more preferably C 10-15a hydrocarbon group which may be saturated or contain one or more double and / or triple bonds and / or which may contain one or more functional groups, preferably selected from the group consisting of hydroxyl, alkoxy, acyloxy, amide, thiol, thioether or phosphorus-containing functional groups, R 2 is H, substituted or unsubstituted C 1-6 Hydrocarbon, or substituted or unsubstituted C 1-6 acyl groups,
[0016] R 3 is selected from substituted or unsubstituted aryl, heteroalkyl, substituted or unsubstituted C 1-31 Hydrocarbyl (which may be saturated or unsaturated), preferably substituted or unsubstituted C 9-31 a hydrocarbon group (which may be saturated or unsaturated);
[0017] The method is carried out by a lysosphingolipid having the formula (2) or a salt thereof:
[0018]
[0019] in:
[0020] W.R. 1 and R 2 As defined for the sphingolipid of formula (1), and
[0021] The method comprises reacting the lysosphingolipid salt of formula (2) or a salt thereof with an ester of formula (3) in the presence of a base in an alcohol solvent:
[0022]
[0023] in
[0024] R 3 As defined for the sphingolipid of formula (1), and
[0025] R 4 is a C1-C4 hydrocarbon group, preferably selected from methyl, ethyl, propyl, isopropyl, butyl or isobutyl, more preferably selected from methyl or ethyl. DETAILED DESCRIPTION
[0026] The present inventors have established for the first time an efficient and economical method for chemically N-acylation of lysosphingolipids (such as D-erythro-sphingosine or 6-hydroxy-D-erythro-sphingosine), analogs thereof or salts thereof, wherein the lysosphingolipids used as starting materials are preferably obtained via synthetic and / or biotechnological methods.
[0027] Surprisingly, the present inventors have found that lysosphingolipids (such as D-erythro-sphingosine or 6-hydroxy D-erythro-sphingosine), analogs thereof or salts thereof can be N-acylated in the presence of a base in an alcoholic solvent using an ester of formula (3):
[0028]
[0029] in
[0030] R 3 As defined for the sphingolipid of formula (1), and
[0031] R 4 is a C1-C4 hydrocarbon group, preferably selected from methyl, ethyl, propyl, isopropyl, butyl or isobutyl, more preferably selected from methyl or ethyl.
[0032] Non-limiting embodiments of various aspects of the invention are described below and illustrated by way of non-limiting examples.
[0033] The terms, definitions and embodiments described throughout the specification of the present invention relate to all aspects and embodiments of the present invention.
[0034] The term "a" is grammatically singular, but it may also refer to, for example, the plural form of the intended compound. For example, the skilled person will understand that in the expression "a lyso-sphingolipid of formula (2)", it is intended not only to provide a single lyso-sphingolipid of formula (2), but also to provide a plurality of lyso-sphingolipids of the same type.
[0035] In formulae representing moieties or groups such as, for example, hydrocarbon groups having formula (5) or (6), the symbol It refers to the point of attachment to another group or atom.
[0036] As used herein, the various functional groups or substituents represented will be understood to have a point of attachment at the functional group or atom with a dash (-). For example, in the case of -OH, it will be understood that the point of attachment is the oxygen atom. If a group is listed without a dash, the point of attachment is indicated by the ordinary and common meaning of the listed group.
[0037] The letters H, Cl, Br, I and F refer to hydrogen, chlorine, bromine, iodine and fluorine atoms, respectively.
[0038] The skilled person will understand that when referring to positions C-1, C-2, C-3, C-4, C-5, etc., reference is always made herein to the corresponding carbon atom of a sphingolipid having formula (1), or the corresponding carbon atom of a lyso-sphingolipid having formula (2), (7), or (8). Positions C-1, C-2, C-3, C-4, C-5 may also be referred to as 1-position, 2-position, 3-position, 4-position, and 5-position, respectively.
[0039] As used herein, the term "alkyl" refers to an acyclic straight or branched chain hydrocarbyl group having 1 to 50 carbon atoms, which may be saturated or contain one or more double and / or triple bonds (thus, forming, for example, an alkenyl or alkynyl group), and / or may be substituted or unsubstituted, as further described herein. Examples of "alkyl" include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl, isopentyl, n-pentyl, neopentyl, n-hexyl, ethenyl, propenyl, 1-butenyl, 2-butenyl, isobutenyl, 1-pentenyl, 2-pentenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 2-methyl-2-butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, methylpentenyl, dimethylbutenyl, ethynyl, propynyl, 1-butynyl, 2-butynyl, pentynyl, and hexynyl, each of which can be substituted or unsubstituted. Typically, the term alkyl refers to a straight chain acyclic hydrocarbon group having 1 to 31 carbons, which can be substituted or unsubstituted.
[0040] As used herein, the term "aryl" refers to an aromatic cyclic hydrocarbon group having 5-14 ring carbon atoms, which may be monocyclic or polycyclic, may contain fused rings, preferably 1 to 3 fused rings or non-fused rings, and may contain one or more heteroatoms, and / or may be substituted or unsubstituted, as further described herein. Examples of "aryl" include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthryl, pyrrolyl, imidazolyl, thienyl, furyl, oxazolyl, thiazolyl, pyridyl, pyrimidinyl, pyrazinyl, triazinyl, and benzofuranyl, each of which may be substituted or unsubstituted. Typically, the term "aryl" refers to substituted or unsubstituted phenyl.
[0041] As used herein, the term "acyl" refers to a group derived from an oxoacid, preferably a carboxylic acid, by removing one or more hydroxyl groups. Acyl groups according to the present invention are typically saturated or unsaturated C 2-32 Acyl groups, which may be substituted or unsubstituted.
[0042] As used herein, the term "alkylene" refers to a divalent saturated or unsaturated aliphatic group derived from a substituted or unsubstituted alkane by removing two hydrogen atoms from different carbon atoms, preferably from terminal carbon atoms. The alkylene group according to the present invention is typically C 6-28 The alkylene group, which may be saturated or contain one or more double and / or triple bonds, and / or may be substituted or unsubstituted, is as further described herein.
[0043] As used herein, the term "substituted" means that the group in question is substituted with a group that typically changes the general chemical characteristics of the group in question. Substituents can be used to change the characteristics of the molecule, such as molecular stability, molecular solubility, and the ability of the molecule to form crystals. Those skilled in the art will recognize other suitable substituents with similar size and charge characteristics that can be used as substitutes in a given situation.
[0044] With respect to the terms "hydrocarbyl", "aryl", "acyl" and "hydrocarbylene", the term substituted means that the group in question is substituted one or several times, preferably one to three times, by one or more groups selected from the group consisting of: hydroxy (which can exist in tautomeric keto form when bound to an unsaturated carbon atom), oxo, C 1-6 -alkoxy (i.e. C 1-6 -alkyl-oxy), C 2-6 -Alkenyloxy, carboxyl, oxo, C 1-6 -alkoxycarbonyl, C 1-6 -alkylcarbonyl, formyl, aryl, aryloxycarbonyl, aryloxy, arylamino, arylcarbonyl, heteroaryl, heteroarylamino, heteroaryloxycarbonyl, heteroaryloxy, heteroarylcarbonyl, amino, mono- and di-(C 1-6 -alkyl)amino, carbamoyl, mono- and di-(C 1-6 -alkyl)aminocarbonyl, amino-C 1-6 -alkyl-aminocarbonyl, mono- and di(C 1-6 -alkyl)amino-C 1-6 -alkyl-aminocarbonyl, C 1-6 -alkylcarbonylamino, cyano, guanidine, urea, C 1-6 -alkyl-sulfonyl-amino, aryl-sulfonyl-amino, heteroaryl-sulfonyl-amino, C 1-6 -alkanoyloxy, C 1-6 -alkyl-sulfonyl, C 1-6 -alkyl-sulfinyl, C 1-6 -alkylsulfonyloxy, nitro, C 1-6 -alkylthio, halogen, wherein any alkyl, alkoxy, etc. representing a substituent can be replaced by hydroxyl, C 1-6 -alkoxy, C 2-6 -Alkenyloxy, carboxyl, C 1-6 -alkylcarbonylamino, halogen, C 1-6 -alkylthio, C 1-6 -alkyl-sulfonyl-amino or guanidino substituted.
[0045] The term "lysosphingolipid" as used herein refers to a sphingolipid that lacks an amide-linked fatty acid at the C-2 position of the sphingoid base backbone. Suitable lysosphingolipids for use in the context of the present invention are sphingoid bases, glycosylated sphingoid bases, and analogs thereof, and can be represented by a lysosphingolipid having formula (2):
[0046]
[0047] in
[0048] W is H or a glycosyl moiety,
[0049] R 1 is H, aryl or C 1-50 Hydrocarbyl, preferably C 1-15 Hydrocarbyl, more preferably C 10-15 a hydrocarbon group, which may be saturated or contain one or more double and / or triple bonds, and / or which may contain one or more functional groups, preferably selected from the group consisting of hydroxyl, alkoxy, acyloxy, amide, thiol, thioether or phosphorus-containing functional groups,
[0050] R 2 is H, substituted or unsubstituted C 1-6 Hydrocarbon, or substituted or unsubstituted C 1-6 acyl group.
[0051] The term "glycosyl moiety" as used herein is defined to include moieties derived from monosaccharides or oligosaccharides (one or more monosaccharide units), wherein the anomeric carbon of the monosaccharide or the anomeric carbon at the reducing end of the oligosaccharide is glycosidically bonded to another chemical entity, and unless otherwise specified, the bond may be an α- or β-glycosidic bond. Glycosyl moieties having more than one monosaccharide unit may represent a linear or branched structure.
[0052] The monosaccharide unit can be any sugar of 5-9 carbon atoms, including aldose (e.g., D-glucose, D-galactose, D-mannose, D-ribose, D-arabinose, L-arabinose, D-xylose, etc.), ketose (e.g., D-fructose, D-sorbose, D-tagatose, etc.), deoxy sugar (e.g., L-rhamnose, L-fucose, etc.), deoxy-amino sugar (e.g., N-acetylglucosamine, N-acetylmannosamine, N-acetylgalactosamine, etc.), uronic acid, ketonic acid (e.g., sialic acid). The monosaccharide unit can form different ring structures, such as a pyranose (six-membered) ring structure or a furanose (five-membered) ring structure.
[0053] The glycosyl moiety according to the present invention may be illustrated in the following format: Galβ1-4Glc1-, wherein the dash (-) represents the point of attachment of the glycosyl moiety, and wherein the glycosyl moiety may be linked via an α or β glycosidic bond, preferably a β glycosidic bond.
[0054] In the context of the present invention, the terms "about," "around," or "approximate" are interchangeably applied to a specific value (e.g., "a temperature of about 25°C," "a temperature of approximately 25°C," or "a temperature of approximately 25°C"), or a range (e.g., "an amount of about 0.1 to about 0.2," "an amount of about 0.1 to about 0.2," or "an amount of approximately 0.1 to approximately 0.2") to indicate a deviation of 0.1% to 10% from the specific value.
[0055] Suitable esters for use in the context of the present invention are typically derived from carboxylic acids and are represented by formula (3).
[0056] In some embodiments, R of the ester having formula (3) 3 is a substituted or unsubstituted C having formula (5) or (6) 9-31 Hydrocarbon:
[0057]
[0058] in
[0059] Q is selected from H, -OH, Cl, Br, I, or F,
[0060] L is a straight chain C 6-28 an alkylene group (which may be saturated or contain one or more double and / or triple bonds), R 6 Is H or -OR 7 , where R 7 is hydrogen or straight chain C 2-30 An acyl group (which may be saturated or contain one or more double bonds).
[0061] In some preferred embodiments, R of the ester having formula (3) 3 is a substituted or unsubstituted C having formula (5) 9-31 Hydrocarbon group.
[0062] Thus, in some preferred embodiments, the ester of formula (3) is an ester of formula (9):
[0063]
[0064] in
[0065] R 4 is a C1-C4 hydrocarbon group, preferably selected from methyl, ethyl, propyl, isopropyl, butyl or isobutyl, more preferably selected from methyl or ethyl;
[0066] Q is selected from H, -OH, Cl, Br, I or F, preferably selected from H or -OH.
[0067] L is a straight chain C6-28 an alkylene group (which may be saturated or contain one or more double and / or triple bonds), R 6 Is H or -OR 7 , where R 7 is hydrogen or straight chain C 2-30 An acyl group (which may be saturated or contain one or more double bonds).
[0068] In some embodiments, for the hydrocarbyl group of formula (5) and for the ester of formula (9), Q is H and L is a linear saturated unsubstituted C 14 -C 28 alkylene, and R 6 It’s H.
[0069] In some embodiments, the ester of formula (3) or the ester of formula (9) is derived from C 18 -C 26 Esters of non-hydroxy fatty acids [N],
[0070] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from stearic acid [N(18:0)].
[0071] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from arachidic acid [N(20:0)].
[0072] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from behenic acid [N(22:0)].
[0073] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from lignoceric acid [N(24:0)].
[0074] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from hexacosanoic acid [N(26:0)].
[0075] In some embodiments, for the hydrocarbyl group of formula (5) and for the ester of formula (9), Q is -OH, L is a linear saturated unsubstituted C 14 -C 28 alkylene, and R 6 It’s H.
[0076] In some embodiments, the ester of formula (3) or the ester of formula (9) is derived from C 18 -C 26 Esters of α-hydroxy fatty acids [A],
[0077] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from α-hydroxystearic acid [A(18:0)].
[0078] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from α-hydroxyarachidic acid [A(20:0)].
[0079] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from α-hydroxybehenic acid [A(22:0)].
[0080] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from α-hydroxylignoceric acid [A(24:0)].
[0081] In some embodiments, the ester of formula (3) or the ester of formula (9) is an ester derived from α-hydroxyhexacosanoic acid [A(26:0)].
[0082] In some embodiments, for the hydrocarbyl group of formula (5) and for the ester of formula (9), Q is H and L is a linear saturated unsubstituted C 14 -C 28 alkylene, and R 6 Yes-OR 7 , where R 7 Is saturated or unsaturated C 18 acyl group.
[0083] The letters in square brackets refer to the shorthand nomenclature developed by Motta et al. (Biochim Biophys Acta., 1993, 1182: 147-151) and expanded by Rabionet et al. (Biochim Biophys Acta, 2014, 1841: 422-434) and Masukawa et al. (Journal of Lipid Research, 2008, 49, 1466-1476), in which non-hydroxy fatty acids (N), α-hydroxy fatty acids (A) and ω-linoleoyloxy fatty acids (EO) can be represented by the letters N, A and EO, respectively, and wherein the number of carbons and the number of unsaturations can be expressed in brackets after the letters N, A, EO.
[0084] In some embodiments, R of the ester having formula (3) or (9) 4 It's methyl.
[0085] In some embodiments, the ester having formula (3) or (9) is a methyl ester selected from the group consisting of methyl stearate, methyl arachidate, methyl behenate, methyl lignocerate, and methyl hexacosanoate.
[0086] In some embodiments, the ester having formula (3) or (9) is a methyl ester selected from the group consisting of methyl α-hydroxystearate, methyl α-hydroxyarachidate, methyl α-hydroxybehenate, methyl α-hydroxylignocerate, methyl α-hydroxyhexacosanoate.
[0087] In some embodiments, R of the ester having formula (3) 4 is a substituted or unsubstituted C having formula (6) 9-31 Hydrocarbon group.
[0088] Thus, in some embodiments, the ester of formula (3) is an ester of formula (10):
[0089]
[0090]
[0091] in
[0092] R 4 is a C1-C4 hydrocarbon group, preferably selected from methyl, ethyl, propyl, isopropyl, butyl or isobutyl, more preferably selected from methyl or ethyl;
[0093] L is a straight chain C 6-28 an alkylene group (which may be saturated or contain one or more double and / or triple bonds), R 6 Is H or -OR 7 , where R 7 is hydrogen or straight chain C 2-30 An acyl group (which may be saturated or contain one or more double bonds).
[0094] The esters used in the context of the present invention can be purchased from well-known manufacturers (e.g. Merck) or can be prepared according to methods known to the skilled person, e.g. by et al., J. Chromatogr. [Journal of Chromatography] 1990, 152, 89-97.
[0095] The present invention describes a process for producing a sphingolipid of formula (1), wherein an ester of formula (3), (9) or (10) is reacted with a lysosphingolipid of formula (2), (7) or (8) in the presence of a base.
[0096] The lysosphingolipids used in the context of the present invention are preferably obtained via synthetic and / or biotechnological methods such as those described in WO 2021170624 A2; or in WO 2019238970 A1; or by Wisse et al., J. Org. Chem. 2015, 80(14), 7258-7265; or by Yadav et al., Tetrahedron Lett. 2003, 44, 2983-2985.
[0097] In some embodiments, the lysosphingolipid of formula (2) is a lysosphingolipid of formula (7), or a salt thereof:
[0098]
[0099] in
[0100] W is H or a glycosyl moiety,
[0101] R 2 is H, substituted or unsubstituted C 1-6 Hydrocarbon, or substituted or unsubstituted C 1-6 acyl groups,
[0102] In some embodiments, the stereochemical configuration of the C-2, C-3, and C-4 carbon atoms of the lysosphingolipid having formula (7) is (2S, 3R, 4E).
[0103] In some preferred embodiments, the lysosphingolipid of formula (7) is D-erythro-sphingosine, or a salt thereof.
[0104] In some embodiments, the lysosphingolipid of formula (2) is a lysosphingolipid of formula (8), or a salt thereof:
[0105]
[0106] in
[0107] W is H or a glycosyl moiety,
[0108] R 2 is H, substituted or unsubstituted C 1-6 Hydrocarbon, or substituted or unsubstituted C 1-6 acyl group.
[0109] In some embodiments, the stereochemical configuration of the C-2, C-3, and C-4 carbon atoms of the lysosphingolipid having formula (8) is (2S, 3S, 4E).
[0110] In some preferred embodiments, the lysosphingolipid having formula (8) is 6-hydroxy-D-ribose-sphingosine.
[0111] In some embodiments, the lysosphingolipids of formula (2), (7), or (8) can be produced or used in the form of a salt, preferably a pharmaceutically acceptable salt.
[0112] In some embodiments, salts of lysosphingolipids having formula (2), (7), or (8) can be formed from the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, polyphosphoric acid, acetic acid, camphorsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, perchloric acid.
[0113] Typically, a lysosphingolipid of formula (2), (7) or (8) is reacted with an ester of formula (3), (9) or (10) in the presence of a base such as an alkoxide.
[0114] Alkoxides for use in the context of the present invention may be represented by alkoxides having formula (4):
[0115] R 5 -O - X +
[0116] (4),
[0117] in
[0118] R 5 is a C1-C4 hydrocarbon group, preferably selected from methyl, ethyl, propyl, isopropyl, butyl or isobutyl, more preferably selected from methyl or ethyl;
[0119] X + is selected from Na + , K + 、Li + or NH4 + cation, preferably Na + .
[0120] In some more preferred embodiments, the lysosphingolipid of formula (2), (7), or (8) is reacted with the ester of formula (3), (9), or (10) in the presence of sodium methoxide.
[0121] The base can be used in a catalytic amount, an equimolar amount or an excess amount.
[0122] In some embodiments, the lysosphingolipid of formula (2), (7) or (8) is in the form of a free base and the base is used in a catalytic amount of about 0.1 to about 0.5 molar equivalents based on the amount of the lysosphingolipid, preferably the base is used in a catalytic amount of about 0.1 to about 0.2 molar equivalents based on the amount of the lysosphingolipid.
[0123] In some embodiments, the lysosphingolipid of formula (2), (7) or (8) is in salt form and the base is used in an amount of about 0.5 to about 1.7 molar equivalents based on the amount of the lysosphingolipid, preferably the base is used in an amount of about 1.2 to 1.4 molar equivalents based on the amount of the lysosphingolipid.
[0124] Typically, the lysosphingolipid, ester, and base are reacted in an alcoholic solvent such as methanol, ethanol, propanol, isopropanol, butanol, or isobutanol.
[0125] In some preferred embodiments, the reaction is carried out in methanol. In certain embodiments, the reaction is carried out in a mixture of one or more alcoholic solvents, such as a mixture of methanol and ethanol, methanol and propanol, methanol and isopropanol, methanol and butanol, methanol and isobutanol, or a mixture of water and aliphatic alcohol.
[0126] Typically, the lysosphingolipid, ester, and base are reacted at a temperature of about 50° C. to about 125° C. Preferably, the reaction is carried out at a temperature of about 60° C. to about 65° C. Thus, in some preferred embodiments, the reaction is carried out at a temperature of about 60° C., 61° C., 62° C., 63° C., 64° C., or 65° C.
[0127] The components of the reactions of the present invention may be combined in any order, and it will be understood that the order of combining the reactants may be adjusted as desired.
[0128] For example, a base can be added to a solution of the lysosphingolipid and the ester. As another example, a solvent can be added to a flask containing the lysosphingolipid and the ester, followed by the addition of a base.
[0129] The lysosphingolipids, esters, and bases, as well as any other reagents used during the reaction, can be added to the reaction as a solid or dissolved in a solvent and in any amount and manner effective for the desired outcome of the reaction.
[0130] The reaction between the ester, base and lysosphingolipid according to the present invention results in the selective N-acylation of the amino group at the C-2 carbon atom of the lysosphingolipid having formula (2), (7) or (8), thereby producing a sphingolipid having formula (1).
[0131] In some embodiments, the sphingolipid having formula (1) is a sphingolipid having formula (11):
[0132]
[0133] in
[0134] W is H or a glycosyl moiety,
[0135] R 2 is H, substituted or unsubstituted C 1-6 Hydrocarbon, or substituted or unsubstituted C 1-6acyl groups,
[0136] R 3 is selected from substituted or unsubstituted aryl, heteroalkyl, substituted or unsubstituted C 1-31 Hydrocarbyl (which may be saturated or unsaturated), preferably substituted or unsubstituted C 9-31 A hydrocarbon group (which may be saturated or unsaturated).
[0137] In some embodiments, the sphingolipid having formula (1) is a sphingolipid having formula (12):
[0138]
[0139] in
[0140] W is H or a glycosyl moiety, R 2 is H, substituted or unsubstituted C 1-6 Hydrocarbon, or substituted or unsubstituted C 1-6 acyl groups,
[0141] R 3 is selected from substituted or unsubstituted aryl, heteroalkyl, substituted or unsubstituted C 1-31 Hydrocarbyl (which may be saturated or unsaturated), preferably substituted or unsubstituted C 9-31 A hydrocarbon group (which may be saturated or unsaturated).
[0142] The sphingolipids of formula (1), (11) or (12) carry an acyl group derived from a carboxylic acid, preferably a fatty acid.
[0143] The acyl group carried by the sphingolipid having formula (1), (11) or (12) can be represented by an acyl group having formula (13):
[0144]
[0145] in
[0146] R 3 is selected from substituted or unsubstituted aryl, heteroalkyl, substituted or unsubstituted C 1-31 Hydrocarbyl (which may be saturated or unsaturated), preferably substituted or unsubstituted C 9-31 A hydrocarbon group (which may be saturated or unsaturated).
[0147] Those skilled in the art will appreciate that an ester of formula (3), (9) or (10) also carries an acyl group of formula (13).
[0148] In some embodiments, R having an acyl group of formula (13) 3 is a substituted or unsubstituted C having formula (5) or (6) 9-31 Hydrocarbon:
[0149]
[0150] in
[0151] Q is selected from H, -OH, Cl, Br, I or F, preferably selected from H or -OH
[0152] L is a straight chain C 6-28 an alkylene group (which may be saturated or contain one or more double and / or triple bonds), R 6 Is H or -OR 7 , where R 7 is hydrogen or straight chain C 2-30 An acyl group (which may be saturated or contain one or more double bonds).
[0153] In some preferred embodiments, R having an acyl group of formula (13) 3 is a substituted or unsubstituted C having formula (5) 9-31 Hydrocarbon group.
[0154] Thus, in some preferred embodiments, the acyl group having formula (13) is an acyl group having formula (14):
[0155]
[0156] in
[0157] Q is selected from H, -OH, Cl, Br, I or F, preferably selected from H or -OH
[0158] L is a straight chain C 6-28 an alkylene group (which may be saturated or contain one or more double and / or triple bonds), R 6 Is H or -OR 7 , where R 7 is hydrogen or straight chain C 2-30 An acyl group (which may be saturated or contain one or more double bonds).
[0159] In some embodiments, R having an acyl group of formula (13) 3 is a substituted or unsubstituted C having formula (6) 9-31 Hydrocarbon group.
[0160] Thus, in some embodiments, the acyl group having formula (13) is an acyl group having formula (15):
[0161]
[0162] in
[0163] L is a straight chain C 6-28 an alkylene group (which may be saturated or contain one or more double and / or triple bonds), R6 Is H or -OR 7 , where R 7 is hydrogen or straight chain C 2-30 An acyl group (which may be saturated or contain one or more double bonds).
[0164] In some embodiments, the acyl group of formula (13) or (14) is derived from C 18 -C 26 Acyl groups of non-hydroxy fatty acids [N],
[0165] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from stearic acid [N(18:0)].
[0166] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from arachidic acid [N(20:0)].
[0167] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from behenic acid [N(22:0)].
[0168] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from lignoceric acid [N(24:0)].
[0169] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from hexacosanoic acid [N(26:0)].
[0170] In some embodiments, for acyl groups having formula (14) and for sphingolipids having formula (16) or (17), Q is -OH, L is a linear saturated unsubstituted C 14 -C 28 alkylene, and R 8 It’s H.
[0171] In some embodiments, the acyl group of formula (13) or (14) is derived from C 18 -C 26 acyl group of α-hydroxy fatty acid [A],
[0172] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from α-hydroxystearic acid [A(18:0)].
[0173] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from α-hydroxyarachidic acid [A(20:0)].
[0174] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from α-hydroxybehenic acid [A(22:0)].
[0175] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from α-hydroxylignoceric acid [A(24:0)].
[0176] In some embodiments, the acyl group having formula (13) or (14) is an acyl group derived from α-hydroxyhexacosanoic acid [A(26:0)].
[0177] In some embodiments, for acyl groups having formula (14) and for sphingolipids having formula (16) or (17), Q is H and L is a linear saturated unsubstituted C 14 -C 28 alkylene, and R 8 Yes-OR 9 , where R 9 Is saturated or unsaturated C 18 acyl group.
[0178] In some embodiments, the acyl group carried by the sphingolipids of the present invention is an acyl group having formula (14), wherein the acyl group having formula (14) is selected from the group consisting of acyl groups having formulae (16)-(24):
[0179]
[0180] In some preferred embodiments, W of the sphingolipid according to the present invention is hydrogen. Thus, in some preferred embodiments, the sphingolipid according to the present invention is ceramide.
[0181] In the context of the present invention, ceramide means a naturally occurring ceramide, an analogue or a derivative thereof. Preferred ceramides are those that occur naturally in humans.
[0182] Naturally occurring human ceramides (CER) include, but are not limited to, CER[NS], CER[AS], CER[EOS], CER[NH], CER[AH] or CER[EOH], CER[NP], CER[AP] or CER[EOP], CER[NDS], CER[ADS] or CER[EODS], where letters in square brackets refer to the abbreviated nomenclature developed by Motta et al. (Biochim Biophys Acta., 1993, 1182: 147-151) and expanded by Rabionet et al. (Biochim Biophys Acta, 2014, 1841: 422-434) and Masukawa et al. (Journal of Lipid Research, 2008, 49, 1466-1476). The letters N, A, and EO represent non-hydroxy fatty acids (N), α-hydroxy fatty acids (A), and ω-linoleoyloxy fatty acids (EO), respectively, where the number of fatty acid carbon atoms and the number of unsaturations can be expressed in parentheses after the letters N, A, and EO. The letters S, H, P, and DS represent D-erythro-sphingosine (S), 6-hydroxy-D-erythro-sphingosine (H), D-ribo-phytosphingosine (P), and D-erythro-dihydrosphingosine (DS), respectively, where the number of sphingosine carbon atoms can be expressed in parentheses after the letters S, H, P, and DS. Ceramides CER[NDS], CER[ADS], or CER[EODS] may also be referred to as CER[NG], CER[AG], or CER[EOG], respectively, where the letter G represents the INCI name for D-erythro-dihydrosphingosine.
[0183] In some embodiments, the sphingolipid having formula (1) or (11) is a ceramide selected from CER[NS], CER[AS], CER[EOS].
[0184] In some preferred embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [N(18:0)S(18)].
[0185] In some embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [N(20:0)S(18)].
[0186] In some embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [N(22:0)S(18)].
[0187] In some embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [N(24:0)S(18)].
[0188] In some embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [N(26:0)S(18)].
[0189] In some preferred embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [A(18:0)S(18)].
[0190] In some embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [A(20:0)S(18)].
[0191] In some embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [A(22:0)S(18)].
[0192] In some embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [A(24:0)S(18)].
[0193] In some embodiments, the sphingolipid having formula (1) or (11) is ceramide CER [A(26:0)S(18)].
[0194] In some embodiments, the sphingolipid having formula (1) or (12) is a ceramide selected from CER[NH], CER[AH], CER[EOH].
[0195] In some preferred embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [N(18:0)H(18)].
[0196] In some embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [N(20:0)H(18)].
[0197] In some embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [N(22:0)H(18)].
[0198] In some embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [N(24:0)H(18)].
[0199] In some embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [N(26:0)H(18)].
[0200] In some preferred embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [A(18:0)H(18)].
[0201] In some embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [A(20:0)H(18)].
[0202] In some embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [A(22:0)H(18)].
[0203] In some embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [A(24:0)H(18)].
[0204] In some embodiments, the sphingolipid having formula (1) or (12) is ceramide CER [A(26:0)H(18)].
[0205] In some embodiments, W of the sphingolipids of the invention and W of the lysosphingolipids of the invention is a glycosyl moiety, and wherein the glycosyl moiety is selected from G1c1-, Gal1-, Galβ1-4G1c1-.
[0206] In some embodiments, W of the sphingolipids of the invention and W of the lysosphingolipids of the invention is a glycosyl moiety, and wherein the glycosyl moiety is an oligosaccharide moiety of a ganglioside selected from GM1a, GM1b, GD1a, GD1b, GD3, GT1b, GT3, GQ1b, GM3, GM4.
[0207] In the context of the present invention, the oligosaccharide portion of GM1a, GM1b, GD1a, GD1b, GD3, GT1b, GT3, GQ1b, GM3 and GM4 can be represented by the following formulae, respectively:
[0208] Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc1-, Neu5Acα2-3Galβ1-3GalNAcβ1-4Galβ1-4Glc1-, Neu5Acα2-3Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glc1-, Galβ1-3GalNAcβ1-4(Neu5Acα2-8Neu5Aca2-3)Galβ1-4Glc1-, Neu5Acα2-8Neu5Acα2-3Galβ1-4Glc1-, Neu5Acα2-3Galβ1-3GalNAcβ1-4(Neu5Acα2-8Neu5Acα2-3)Galβ1-4Glc1-, Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3Galβ1-4Glc1-, Neu5Acα2-8Neu5Aca2-3Galβ1-3GalNAcβ1-4(Neu5Acα2-8Neu5Acα2-3)Galβ1-4Glc1-, Neu5Acα2-3GalB1-4Glc1- Neu5Acα2-3Gal1-,
[0210] As used herein, the term "oligosaccharide moiety of a ganglioside" is defined as comprising a glycosyl moiety derived from a ganglioside, wherein the anomeric carbon at the reducing end of the oligosaccharide moiety of the ganglioside is bound to another chemical entity by a glycosidic bond, which may be an α- or β-glycosidic bond, preferably a β-glycosidic bond. In the context of the present invention, the terms oligosaccharide moiety and glycosyl moiety are used interchangeably.
[0211] In some embodiments, W of the sphingolipids of the invention and W of the lysosphingolipids of the invention is a glycosyl moiety, wherein the glycosyl moiety is a glycosyl moiety of a human milk oligosaccharide, and wherein the human milk oligosaccharide is preferably selected from LNT, LNnT, LNH, LNnH, 2′FL, 3FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, 3′SL, 6′SL, FSL, LSTa, LSTb, LSTc and DSLNT.
[0212] In the context of the present invention, the glycosyl moiety of LNT, LNnT, LNH, LNnH, 2′FL, 3FL, DFL, LNFP-I, LNFP-II, LNFP-III, LNFP-V, LNDFH-I, 3′SL, 6′SL, FSL, LSTa, LSTb, LSTc, and DSLNT can be represented by the following formulae, respectively:
[0213] Galp1-3GlcNAcβ1-3Galβ1-4Glc1-, Galβ1-4GlcNAcβ1-3Galβ1-4Glc1-, Galβ1-3GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)Galβ1-4Glc1-, Galβ1-4GlcNAcβ1-3Galβ1-4GlucNAcβ1-3Galβ1-4Glc1-, Fucα1-2Galβ1-4Glc1-, Galβ1-4(Fucα1-3)Glc1-, Fucα1-2Galβ1-4(Fuca1-3)Glc1-, Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glc1-, Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4Glc1-, Galβ1-3(Fucα1-3)GlcNAcβ1-3Galβ1-4Glc1-, Galβ1-3GlcNAcβ1-3Galβ1-4(Fucα1-3)Glc1-, Fucα1-2Galβ1-3(Fuca1-4)GlcNacβ1-3Galβ1-4Glc1-, Neu5Acα2-3Galβ1-4Glc1-, Neu5Acα2-6Galβ1-4Glc1-, Neu5Acα2-3Galβ1-4(Fucα1,3)Glc1-, Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-4Glc1-, Galβ1-3(Neu5Acα2-6)GlcNAcβ1-3Galβ1-4Glc1-, Neu5Acα2-6Galβ1-3GlcNAcβ1-3Galβ1-4Glc1-, Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GlcNAcβ1-3Galβ1-4Glc1-, .
[0214] In some embodiments, W of the sphingolipids of the invention and W of the lysosphingolipids of the invention is a glycosyl moiety, and wherein the glycosyl moiety is an oligosaccharide moiety of a glycosphingolipid selected from the gala series [SP0509], neogala series, globo series [SP0502], isoglobo series [SP0506], lacto series [SP0504], neolacto series [SP0505], arthro series [SP0508], muco series, schisto series, spirometo series, or protected analogs thereof.
[0215] The alphanumeric string in square brackets indicates a link to the website https: / / www.lipidmaps.org / where detailed chemical formula and structural information of the corresponding compound can be found.
[0216] The sphingolipids produced by the method of the present invention can be separated from the reaction mixture. The separation can be carried out by standard methods known to those skilled in the art. A preferred method for isolating the sphingolipids according to the present invention is via precipitation from the reaction mixture. Precipitation can be achieved, for example, by partially removing the reaction solvent by evaporation (i.e., concentrating the reaction mixture), or by adding another solvent to the reaction mixture, or by changing the temperature or pressure, or by adding other solutes, or a combination of these methods.
[0217] In some embodiments, the sphingolipids according to the present invention are separated from the reaction mixture via precipitation, wherein the precipitation is achieved by cooling the reaction mixture to a temperature of about 0°C to about 25°C, preferably about 0°C to about 10°C.
[0218] The sphingolipids according to the present invention can be isolated in different polymorphic forms. The polymorphic forms as referred to herein may include crystalline and amorphous forms as well as solvate and hydrate forms, which can be further characterized as follows:
[0219] i. Crystalline forms have molecules with different arrangements and / or conformations in the crystal lattice.
[0220] ii. Amorphous forms consist of disordered arrangements of molecules with no discernible crystal lattice.
[0221] iii. Solvates are crystalline forms that contain stoichiometric or non-stoichiometric amounts of a solvent. If the incorporated solvent is water, the solvate is often called a hydrate.
[0222] Examples
[0223] The following working examples describe non-limiting embodiments of the present invention and are given solely for the purpose of illustrating the invention.
[0224] General methods and materials:
[0225] Recorded with a Bruker Avance II (400 MHz) spectrometer 1 H NMR and 13 C NMR. 1 H and 13 C chemical shifts are given in ppm (δ) relative to internal standards of tetramethylsilane (δ = 0.00), CDCl3 (δ = 7.26), CD3OD (δ = 3.31), and DMSO-d5 (δ = 2.50). LCMS analysis was performed using a SCIEX Triple Quad TM 4500 LC-MS / MS system.
[0226] Example 1. General procedure for N-acylation of sphingoid bases
[0227] The sphingoid base or its salt is dissolved in 5-10 volumes of a short-chain aliphatic alcohol, most preferably methanol. A base (0.1-1.7 eq), typically sodium methoxide or potassium methoxide, is added and the mixture is stirred at room temperature for 30-60 minutes. An ester of a fatty acid, preferably a fatty acid methyl ester, is added and the reaction mixture is stirred at a temperature between 50°C and 60°C until the reaction is complete. The reaction mixture is cooled to a temperature between 25°C and 18°C and stirred for 30-120 minutes, and then further cooled to a temperature between 10°C and 0°C and stirred for 4-8 hours. A solid suspension is formed, which is filtered and washed twice with a short-chain aliphatic alcohol (most preferably methanol, ethanol, propanol or isopropanol). Typical yields and purities range from 75% to 98%.
[0228] 1.1 Synthesis of N-stearoyl-D-erythro-sphingosine (25), CER[N(18:0)S(18)]
[0229]
[0230] N-stearoyl-D-erythro-sphingosine (25) was synthesized from D-erythro-sphingosine and methyl stearate according to the general procedure of Example 1.
[0231] 1 H-NMR (500MHz, CDCl3) δ (ppm) = 6.26 (d, J = 7.5Hz, 1H), 5.82-5.75 (m, 1H), 5.53 (dd t,J=15.3,6.4,1.4Hz,1H),4.34-4.30(m,1H),3.95(dd,J=11.3,3.8Hz,1H),3.91 (dq,J=7.6,3.8Hz,1H),3.71(dd,J=11.3,3.4Hz,1H),2.35(s,2H),2.26-2.21(m, 2H),2.06(q,J=7.3Hz,2H),1.64(p,J=7.6Hz,2H),1.26(s,53H),0.91-0.86(m,6H)
[0232] 13 C-NMR (126MHz, CDCl3) δ (ppm) = 173.94, 134.32, 128.78, 74.66, 62.50, 54.51, 36.83, 32.27, 31.91, 29. 69,29.68,29.65,29.63,29.61,29.50,29.48,29.36,29.35,29.28,29.22,29.11,25.75,22.68,14.10.
[0233] ESI-MS: 588.55[M+Na] + 、566.61[M+H] + 、548.21[(M+H)-3H2O] + 、530.58[(M+H)-2H2O] + 、518.62[(M+H)-3H2O] + .
[0234] 1.2 Synthesis of N-stearoyl 6-hydroxy-D-erythro-sphingosine (26), CER[N(18:0)H(18)]
[0235]
[0236] N-stearoyl 6-hydroxy-D-erythro-sphingosine (26) was synthesized from 6-hydroxy-D-erythro-sphingosine and methyl stearate according to the general procedure of Example 1.
[0237] ESI-MS: 564.54 [M-H2O] + 、604.45[M+Na] + 、582.50[M+H] + .
[0238] 1.3 Synthesis of N-stearoyl-D-erythro-dihydrosphingosine (27), CER[N(18:0)DS(18)]
[0239]
[0240] N-stearoyl-D-erythro-dihydrosphingosine (27) was synthesized from D-erythro-dihydrosphingosine and methyl stearate according to the general procedure of Example 1.
[0241] 1 H-NMR (500MHz, CD3OD) δ (ppm) = 5.74-5.67 (m, 1H), 5.49-5.43 (m, 1H), 4.36 (d, J = 7.8Hz, 1H), 4.3 0(d,J=7.8Hz,1H),4.18(dd,J=10.1,4.3Hz,1H),4.11(t,J=7.2Hz,1H),4.02-3.97(m,1H),3.89 3.81(m,3H),3.75(dd,J=11.6,4.6Hz,1H),3.61-3.56(m,4H),3.50(dd,J=9.6,3.4Hz,1H),3.44 -3.38(m,1H),3.34(p,J=1.6Hz,2H),3.33-3.30(m,1H),2.21-2.15(m,2H),2.06-1.9 9(m,2H),1.59(t,J=7.1Hz,2H),1.40-1.34(m,2H),1.28(s,46H),0.91-0.86(m,6H).
[0242] 13 C-NMR (126MHz, CD3OD) δ (ppm) = 211.86, 175.28, 134.75, 130.11, 104.47, 103.72, 8 0.44,78.38,78.12,77.86,76.29,75.73,75.58,74.23,74.05,72.62,71.88,69.65 ,69.27,62.04,61.52,54.06,36.99,32.88,32.44,30.22,30.20,30.19,30.17,30.16,30.14,30.09,30.08,29.99,29.92,29.85,29.84,29.82,26.49,23.14,14.23.
[0243] ESI-MS: 568.71[M+H] + 、590.67[M+Na] + .
Claims
1. A method for producing a sphingolipid having formula (1): in W is H or a glycosyl moiety, R 1 is H, aryl or C 1-50 Hydrocarbyl, preferably C 1-15 Hydrocarbyl, more preferably C 10-15 a hydrocarbon group which may be saturated or contain one or more double and / or triple bonds and / or which may contain one or more functional groups, which are preferably selected from the group consisting of hydroxyl, alkoxy, acyloxy, amide, thiol, thioether or phosphorus-containing functional groups, R 2 is H, substituted or unsubstituted C 1-6 Hydrocarbon, or substituted or unsubstituted C 1-6 Acyl, R 3 is selected from substituted or unsubstituted aryl, heteroalkyl, saturated or unsaturated, substituted or unsubstituted C 1-31 The hydrocarbon group may be saturated or unsaturated, substituted or unsubstituted C 9-31 Hydrocarbon; The method is carried out by a lysosphingolipid having the formula (2) or a salt thereof: in W.R. 1 and R 2 as defined for the sphingolipid of formula (1), and The method comprises reacting the lysosphingolipid salt of formula (2) or a salt thereof with an ester of formula (3) in the presence of a base in an alcohol solvent: in R 3 as defined for the sphingolipid of formula (1), and R 4 is a C1-C4 hydrocarbon group, preferably selected from methyl, ethyl, propyl, isopropyl, butyl or isobutyl, more preferably selected from methyl or ethyl.
2. The method according to claim 1, wherein: The base is an alkoxide having the formula (4): R5--00x (4), in R 5 is a C1-C4 hydrocarbon group, preferably selected from methyl, ethyl, propyl, isopropyl, butyl or isobutyl, more preferably selected from methyl or ethyl; X + Is selected from Na + , K + , Li + or NH4 + The cation is preferably Na + .
3. The method according to any one of claims 1 or 2, wherein: About 0.1 to about 1.7 molar equivalents of the base are used based on the amount of the lysosphingolipid of formula (2).
4. The method according to any one of claims 1 to 3, wherein: The lysosphingolipid of formula (2) is in the form of a salt, and wherein about 0.5 to about 1.7 molar equivalents of the base are used based on the amount of the lysosphingolipid of formula (2).
5. The method according to claim 4, wherein: The salt is a hydrochloride, hydrobromide, sulfate, bisulfate, phosphate, polyphosphate, acetate, p-toluene sulfate, methane sulfate, trifluoromethane sulfate or perchlorate of the lysosphingolipid of formula (2), preferably a hydrochloride of the lysosphingolipid of formula (2).
6. The method according to any one of claims 1 to 5, wherein: The lysosphingolipid of formula (2) is in the form of a free base, and the base is used in an amount of about 0.1 to about 0.5 molar equivalents based on the amount of the lysosphingolipid of formula (2).
7. The method according to any one of claims 1 to 6, wherein: The alcohol is a C1-C7 alcohol or a mixture of C1-C7 alcohols.
8. The method according to claim 7, wherein: The alcohol is a C1-C3 alcohol, preferably methanol.
9. The method according to any one of claims 1 to 8, wherein: R 2 It's hydrogen.
10. The method according to any one of claims 1 to 9, wherein: W is hydrogen.
11. The method according to any one of claims 1 to 9, wherein: W is a glycosyl moiety, wherein the glycosyl moiety is preferably selected from Glc1-, Gal1-, Galβ1-4Glc1-.
12. The method according to any one of claims 1 to 11, wherein: R 3 is a substituted or unsubstituted C having formula (5) or (6) 9-31 Hydrocarbon: in Q is selected from H, -OH, Cl, Br, I or F, preferably selected from H or -OH L is a straight chain C which may be saturated or contain one or more double and / or triple bonds. 6-28 Hydrocarbylene, R 6 Is H or -OR 7 , where R 7 It is hydrogen or a straight-chain C which may be saturated or contain one or more double bonds 2-30 Acyl.
13. The method according to any one of claims 1 to 12, wherein: The lysosphingolipid of formula (2) is selected from the group consisting of lysosphingolipids of formula (7) and (8) or salts thereof: Where W and R 2 As defined for the lysosphingolipid of formula (2).
14. The method according to any one of claims 1 to 13, wherein: The lysosphingolipid of formula (2) is selected from the group consisting of d-erythro-sphingosine and 6-hydroxy-d-erythro-sphingosine or salts thereof.
15. The method according to any one of claims 1 to 14, wherein: The lysosphingolipid of formula (2) is d-erythro-sphingosine or a salt thereof.
16. The method according to any one of claims 1 to 14, wherein: The lysosphingolipid of formula (2) is 6-hydroxy-d-erythro-sphingosine or a salt thereof.
17. The method according to any one of claims 1 to 16, wherein: The ester of formula (3) is a fatty acid methyl ester selected from the group consisting of methyl stearate, methyl arachidate, methyl behenate, methyl lignocerate, methyl hexacosanoate, methyl α-hydroxystearate, methyl α-hydroxyarachidate, methyl α-hydroxybehenate, methyl α-hydroxylignocerate and methyl α-hydroxyhexacosanoate.
18. The method according to any one of claims 1 to 17, wherein: The sphingolipid of formula (1) is a ceramide selected from the group consisting of: CER[N(18:0)S(18)], CER[N(20:0)S(18)], CER[N(22:0)S(18)], CER[N(24:0)S(18)], CER[N(26:0)S(18)], CER[N(18:0)H(18)], CER[N(20:0)H(18)], CER[N(22:0)H(18)], CER[N(24:0)H(18)] and CER[N(26:0)H(18)].
19. The method according to claim 18, wherein: The sphingolipid of formula (1) is a ceramide selected from the group consisting of CER[N(18:0)S(18)] and CER[N(18:0)H(18)].
20. The method according to any one of claims 1 to 17, wherein: The sphingolipid of formula (1) is a ceramide selected from the group consisting of: CER[A(18:0)S(18)], CER[A(20:0)S(18)], CER[A(22:0)S(18)], CER[A(24:0)S(18)], CER[A(26:0)S(18)], CER[A(18:0)H(18)], CER[A(20:0)H(18)], CER[A(22:0)H(18)], CER[A(24:0)H(18)], CER[A(26:0)H(18)].
21. The method according to claim 20, wherein: The sphingolipid of formula (1) is a ceramide selected from the group consisting of CER[A(18:0)S(18)] and CER[A(18:0)H(18)].
